A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.
Trial Details
- NCT ID
- NCT06531486
- Phase
- PHASE1
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Status
- RECRUITING
- Cancer Type
- Endometrial Cancer Uterine Cancer
- Interventions
- Locations (sample)
- Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
- Patients must meet all of the following criteria for admission:
- Volunteer to participate in clinical trials and sign an informed consent form (ICF).
- Age ≥18 years old, ≤75 years old, regardless of gender.
- Phase Ia: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors for whom no standard therapy is avail…
For full eligibility, visit ClinicalTrials.gov.